Clinical Study

Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy

Table 4

Within- and between-group comparisons of relative changes (%) in lipid profile and tumor necrosis factor-alpha (TNF-) serum level at 4 and 24 weeks.

CharacteristicsETA + MTX ( = 22)MTX ( = 13)Comparison between groups
( relative change)
Mean ± SDAbsolute changeRelative change (%)Mean ± SD Absolute changeRelative change (%)

Total cholesterol, mg/dL
 Baseline187.9 ± 38.1170.6 ± 42.70.22
 4 weeks178.5 ± 38.6−9.45.0172.8 ± 32.7+2.21.30.18
 24 weeks182.7 ± 44.8−5.22.8188.9 ± 33.0+18.310.70.04
Triglycerides, mg/dL
 Baseline150.4 ± 75.1127.4 ± 51.60.34
 4 weeks141.8 ± 57.4−8.55.7129.3 ± 51.9+1.91.50.96
 24 weeks151.3 ± 61.2+0.90.6151.8 ± 74.2+24.519.20.62
HDL-C, mg/dL
 Baseline48.1 ± 15.644.4 ± 6.90.34
 4 weeks52.0 ± 15.8**+3.98.245.5 ± 9.8+1.22.60.22
 24 weeks57.1 ± 13.9+9.018.747.1 ± 9.7+2.76.10.04
LDL-C, mg/dL
 Baseline100.7 ± 25.9100.5 ± 39.20.99
 4 weeks99.7 ± 30.0−1.01.0101.1 ± 31.6+0.60.60.40
 24 weeks97.3 ± 44.7−3.43.4109.6 ± 27.9+9.09.00.24
TNF-, pg/mL
 Baseline129.14 ± 207.742.36 ± 23.50.88
 4 weeks219.7 ± 228.6*+90.670.233.9 ± 12.9−8.319.80.02
 24 weeks337.4 ± 205.9+208.2161.250.7 ± 24.1+8.219.60.01

ETA + MTX: etanercept plus methotrexate; MTX: methotrexate as monotherapy; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SD: standard deviation. Absolute change is the difference at 4 or 24 weeks versus baseline; relative change is the percentage change at 4 or 24 weeks versus baseline values. : relative change between groups is a comparison of the differences in relative change (%) at 4 and 24 weeks between groups. The values for the calculations were obtained with unpaired Student’s tests. Intragroup comparisons between 4 and 24 weeks versus baseline were calculated with paired Student’s -tests.
* , **, , and .